ACET
Adicet Bio, Inc.
Next earnings Aug 5, 2026 · consensus $-2.11 EPS
Last earnings +1.5% on 2026-05-13
$8.37
▲ +5.95%$8.37▼ -17.59%
over 1Y
L $6.11EODHDH $16.64
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.9%
1W+1.7%
1M-1.5%
3M+29.4%
YTD-5.1%
1Y-17.6%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.21x).
Return on equity -73.4% · latest
Adicet Bio, Inc. shows limited reported revenue, and -73.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$61.4M | -$72.6M | -$152M | -$128M | -$122M |
| Net income | -$62.0M | -$69.8M | -$143M | -$117M | -$117M |
| Diluted EPS | -$2.00 | -$1.70 | -$3.31 | -$21.33 | -$16.95 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$41.4M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-145.4%
FCF yield-120.7%
Quality & risk
ROIC (est.)-60.6%
Free cash flow-$97.0M
Total debt—
Net cash$38.9M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-88.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-05-20). Worth a closer look.
- 8-K Shareholder vote2026-06-18
- 10-K/A Restated periodic report2026-05-20
- 8-K Earnings results2026-05-13
- 10-Q Quarterly report2026-05-13
- DEF 14A Proxy statement2026-04-29
- 8-K Unregistered share sales2026-04-28
- 8-K Earnings results2026-03-12
- S-3 Shelf registration (potential raise)2026-03-12
- 10-K Annual report2026-03-12
Recent filings
all on EDGAR ↗4Period ending 2026-06-192026-06-23open ↗4Period ending 2026-06-192026-06-23open ↗4Period ending 2026-06-212026-06-23open ↗4Period ending 2026-06-212026-06-23open ↗4Period ending 2026-06-212026-06-23open ↗4Period ending 2026-06-212026-06-23open ↗4Period ending 2026-06-212026-06-23open ↗4Period ending 2026-06-212026-06-23open ↗8-KPeriod ending 2026-06-172026-06-18open ↗10-K/APeriod ending 2025-12-312026-05-20open ↗SCHEDULE 13G/AFiling2026-05-15open ↗S-8 POSFiling2026-05-13open ↗
Frequently asked
- Is Adicet Bio, Inc. (ACET) a buy?
- ACET currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.21x).
- What is Adicet Bio, Inc.'s quality score?
- ACET scores 46.641025641025635/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001720580, latest 10-Q filed 2026-05-13) · EODHD · as of 6/22/2026, 11:29:22 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.